Filing Flows › Comparisons › ZVRA vs SPRY
Zevra Therapeutics vs ARS Pharmaceuticals: ZVRA and SPRY compared
Zevra Therapeutics is the larger company: $37.8M of revenue in its latest quarter (Q3 2026) against $37.7M for ARS Pharmaceuticals (Q3 2026). Zevra Therapeutics is growing faster (+45% against +16% a year earlier). Zevra Therapeutics is more profitable, with an operating margin of 30.7% against -90.6%.
Where the money goes: ZVRA and SPRY
Zevra Therapeutics (ZVRA) · Q3 2026
Zevra Therapeutics, Q3 2026: revenue $37.8M (+45% year over year), operating margin 30.7%, net earnings $19.2M, operating cash flow $10.0M. The chart follows the revenue to costs, profit and cash.
ARS Pharmaceuticals (SPRY) · Q3 2026
ARS Pharmaceuticals, Q3 2026: revenue $37.7M (+16% year over year), operating margin -90.6%, net loss $35.6M, operating cash flow −$33.7M. The chart follows the revenue to costs, profit and cash.
| Zevra Therapeutics (ZVRA) | ARS Pharmaceuticals (SPRY) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $37.8M | $37.7M |
| Revenue growth, Y/Y | +45% | +16% |
| Operating margin | 30.7% | -90.6% |
| Net earnings | $19.2M | −$35.6M |
| Net margin | 50.9% | -94.4% |
| Operating cash flow | $10.0M | −$33.7M |
| Free cash flow | $9.8M | — |
| Market value | $636M | — |
| P/E | 8.5× | — |
| Analysts’ mean target | $25.25 | — |
Where the revenue comes from
ARS Pharmaceuticals
- Product: $33.4M (89%)
- Revenue Under Supply Agreements: $2.6M (7%)
- Revenue Under Collaboration Agreements: $1.7M (4%)
Questions
Which is bigger, Zevra Therapeutics or ARS Pharmaceuticals?
Zevra Therapeutics is the larger company: $37.8M of revenue in its latest quarter (Q3 2026) against $37.7M for ARS Pharmaceuticals (Q3 2026).
Is Zevra Therapeutics or ARS Pharmaceuticals growing faster?
Zevra Therapeutics is growing faster (+45% against +16% a year earlier).
Which is more profitable, Zevra Therapeutics or ARS Pharmaceuticals?
Zevra Therapeutics is more profitable, with an operating margin of 30.7% against -90.6%.
More: Zevra Therapeutics earnings · how Zevra Therapeutics makes money · ARS Pharmaceuticals earnings · how ARS Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 3, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.